Shares of Fate Therapeutics (NASDAQ:FATE) have received an average recommendation of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.17.
Several research analysts recently commented on FATE shares. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a report on Tuesday, January 9th. ValuEngine raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright lowered shares of Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price target on the stock. in a research report on Tuesday, March 6th. BMO Capital Markets upped their price target on shares of Fate Therapeutics from $7.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 6th. Finally, Wells Fargo reaffirmed an “outperform” rating and set a $19.00 price target (up from $10.00) on shares of Fate Therapeutics in a research report on Tuesday, March 6th.
FATE traded down $0.02 during trading hours on Friday, hitting $11.32. 252,480 shares of the company’s stock were exchanged, compared to its average volume of 718,479. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $14.45. The stock has a market capitalization of $608.99, a price-to-earnings ratio of -11.10 and a beta of 1.74. The company has a current ratio of 9.29, a quick ratio of 9.29 and a debt-to-equity ratio of 0.19.
Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts predict that Fate Therapeutics will post -0.94 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Monashee Investment Management LLC bought a new stake in Fate Therapeutics during the fourth quarter worth $1,833,000. 683 Capital Management LLC raised its position in Fate Therapeutics by 25.8% during the fourth quarter. 683 Capital Management LLC now owns 853,800 shares of the biopharmaceutical company’s stock worth $5,217,000 after acquiring an additional 175,000 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Fate Therapeutics by 167.6% in the third quarter. Neuberger Berman Group LLC now owns 133,000 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 83,300 shares during the period. J. Goldman & Co LP bought a new position in shares of Fate Therapeutics in the fourth quarter valued at about $1,277,000. Finally, Two Sigma Investments LP bought a new position in shares of Fate Therapeutics in the fourth quarter valued at about $1,043,000. 66.41% of the stock is currently owned by hedge funds and other institutional investors.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.